openPR Logo
Press release

Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report

05-07-2018 08:04 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Cancer Immunotoxins Market & Clinical Pipeline Insight

“Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020” Report Highlights:

* Introduction to Immunotoxins
* Cancer Immunotoxins Therapy Analysis
* Advantages of Immunotoxins upon other Anticancerous Drugs
* Applications of Immunotoxins to Multiple Cancer Therapies
* Global Cancer Immunotoxins Market Future Prospects
* Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase
* Global Cancer Immunotoxins Clinical Pipeline: 52 Cancer Immunotoxins
* Majority Cancer Immunotoxins in Preclinical Phase: 21 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Cancer-Immunotoxins-Market-&-Clinical-Pipeline-Insight-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Introduction to Immunotoxins



2. Immunotoxins: The Three Generations & Advancements



3. Sources of Toxins

3.1 Plant Toxins

3.2 Bacterial Toxins



4. Production of Immunotoxins



5. Types of Immunotoxins

5.1 Anthrax Based Toxins

5.2 Diphtheria Toxin (DT) & DT Derivatives

5.3 Pseudomonas Exotoxin (PE) & PE Derivatives

5.4 Ribosome Inactivating Proteins Based Immunotoxins

5.4.1 Ricin

5.4.2 Saporin based Immunotoxins

5.4.3 Recombinant Constructs of RIP I Toxins

5.5 Ribonucleases based Immunotoxins

5.6 Proapoptotic Proteins as Targeted Immunotoxins



6. Cancer Immunotoxins Therapy Analysis

6.1 Immunotoxins for Hematologic Malignancies

6.1.1 Denileukin Diftitox (ONTAK, DAB389IL-2)

6.1.2 LMB-2 (anti-Tac[Fv]-PE38)

6.1.3 Moxetumomab Pasudotox

6.1.4 A-dmDT390-bisFv (UCHT1)

6.1.5 DT2219ARL

6.1.6 HuM195-Gelonin

6.2 Immunotoxins for Solid Tumors

6.2.1 SS1P

6.2.2 RG7787

6.2.3 Oportuzumab Monatox

6.2.4 VB6-845

6.2.5 D2C7-(scdsFv)-PE38KDEL



7. Advantages of Immunotoxins upon other Anticancerous Drugs



8. Applications of Immunotoxins

8.1 Immunotoxins against Solid Tumors

8.1.1 Immunotoxin against Colon Carcinoma

8.1.2 Immunotoxin against Breast Cancer & Sarcoma

8.1.3 Immunotoxin against Glioma & Head & Neck Squamous Cell Carcinoma

8.1.4 Immunotoxin against Prostate & Lung Cancer

8.2 Immunotoxins against Leukemias

8.3 Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell Reservoirs



9. Global Cancer Immunotoxins Market Outlook

9.1 Current Market Scenario

9.2 Cancer Immunotoxins Clinical Pipeline Overview



10. Global Cancer Immunotoxins Market Dynamics

10.1 Favorable Parameters

10.1.1 Large Segment of Patient Still Devoid of Appropriate Medication

10.1.2 Cancer: A Severe Pathological Condition

10.1.3 Unmet Requirement of Completely Curative Agents

10.1.4 Unwanted Effects of the Existing Drugs

10.2 Commercialization Challenges

10.2.1 Stern Regulatory Guidelines: A Major Hurdle

10.2.2 Never Ending Phase of Research & Development

10.2.3 Conduction of Clinical Trials

10.2.4 Funding Research & Development: A Super Costly Affair

10.2.5 Immunogenicity of Immunotoxins



11. Global Cancer Immunotoxins Market Future Prospects



12. Global Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase

12.1 Research

12.2 Preclinical

12.3 Phase-I

12.4 Phase-I/II

12.5 Phase-II

12.6 Phase-II/III

12.7 Phase-III



13. Discontinued & No Development in Cancer Immunotoxins Clinical Pipeline by Company, Indication & Phase

13.1 No Development Reported

13.2 Discontinued

13.3 Suspended



14. Competitive Landscape

14.1 AbbVie

14.2 AbGenomics

14.3 Agensys

14.4 Ambrx

14.5 Amgen

14.6 AREVA Med

14.7 Bayer HealthCare

14.8 Biotest

14.9 Celldex Therapeutics

14.10 CuraGen Corporation

14.11 Genentech

14.12 Genmab

14.13 Heidelberg Pharma

14.14 ImmunoGen

14.15 Neurocrine Biosciences

14.16 Research Corporation Technologies

14.17 Sanofi

14.18 Seattle Genetics

14.19 Sorrento Therapeutics

14.20 Spirogen

Figure 2-1: Immunotoxins & Their Recombinant Forms

Figure 3-1: Sources of Toxins

Figure 4-1: Steps Involved in Production of Immunotoxins

Figure 5-1: Different Types of Immunotoxins

Figure 5-2: Mechanism of Action of Anthrax Based Immunotoxins

Figure 5-3: Composition of the Diphtheria Derived Toxins

Figure 5-4: Steps Involved in Apoptosis by Diphtheria Derived Immunotoxins

Figure 5-5: Domains of PE with Their Specificities

Figure 5-6: Mode of Apoptosis Taken by Pseudomonas Exotoxin (PE) & PE Derivatives

Figure 6-1: Major Targets of Immunotoxins as Anticancer Agents

Figure 6-2: Some of Important Immunotoxins Targeting Hematological Malignancies

Figure 6-3: Some of Important Immunotoxins Targeting Solid Tumors

Figure 8-1: Major Applications of Immunotoxins

Figure 9-1: Cancer Immunotoxins Pipeline by Phase (%), 2016

Figure 9-2: Cancer Immunotoxins Pipeline by Phase (Numbers), 2016

Figure 9-3: Cancer Immunotoxins Pipeline by Phase (%), 2016

Figure 9-4: Cancer Immunotoxins Pipeline by Phase (Numbers), 2016

Figure 10-1: Favorable Parameters for Global Cancer Immunotoxins Market

Figure 10-2: Commercialization Challenges for Global Cancer Immunotoxins Market

Figure 14-1: AbGenomics - Clinical Pipeline

Figure 14-2: Amgen - Clinical Pipeline

Figure 14-3: Biotest – Clinical Pipeline

Figure 14-4: Genmab - Clinical Pipeline

Figure 14-50: Genmab - Clinical Pipeline

Figure 14-6: Neurocrine Biosciences – Clinical Pipeline

Figure 14-7: Sorrento Therapeutics – Clinical Pipeline



Table 5-1: Immunotoxins in Clinical Development using Diphtheria as a Toxin Moiety

Table 5-2: Clinically evaluated/under evaluation PE-based Immunotoxins against Hematologic Malignancies

Table 5-3: Clinically evaluated/under evaluation PE-based Immunotoxins against Solid Tumors

Table 5-4: Clinical Trials in Patients with Saporin Containing Immunotoxins

Table 6-1: Immunotoxins for Leukemia

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 Report here

News-ID: 1040840 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Immunotoxin

Global Immunotoxins Market Set for Rapid Growth and Trend, by 2023
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Cancer Immunotoxins Market Cancer Immunotoxins Clinical Pipeline Report 2020
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Immunotoxins 2. Immunotoxins: The Three Generations & Advancements 3. Sources of Toxins 3.1 Plant Toxins 3.2 Bacterial Toxins 4. Production of Immunotoxins 5. Types of Immunotoxins 5.1 Anthrax Based Toxins 5.2 Diphtheria Toxin (DT) & DT Derivatives 5.3 Pseudomonas Exotoxin (PE) & PE Derivatives 5.4 Ribosome Inactivating Proteins Based Immunotoxins
Immunotoxins Market: Industry Overview and Key Factors
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Immunotoxins Market - Global Industry Analysis 2023
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Growth of the Global Immunotoxins Market to be Driven by Increasing Prevalence o …
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting
Increasing Global Prevalence of Cancer Drives Immunotoxins Market
Immunotoxins are proteins that include a toxin along with an antibody or growth factor that binds specifically to target. An immunotoxin consists of a specific cell-targeting constituent, usually a monoclonal antibody (mAb) linked to a cell-killing toxin. Chemical conjugation of antibody to whole protein toxin creates immunotoxins, lacking of its natural binding domain. Immunotoxins are created in Escherichia coli that are distorted with a plasmid encoding the recombinant toxin. Harvesting